Leiden, 29 June 2023. BIMINI Biotech has raised an additional €250,000 investment from Libertatis Ergo Holding B.V. to support the development of first-in-class therapeutics for haematological cancers.

The financing will be combined with Eurostars funding to advance BIMINI’s lead WASp-targeting candidates in collaboration with the Institute of Oncology Research in Switzerland and InnoSer.

Progressing BIMINI’s WASp programme

The investment supports development of BM-011, a small-molecule WASp modulator originally discovered by the group of Prof. Francesco Bertoni at the Institute of Oncology Research and subsequently licensed by BIMINI.

The programme focuses on lead optimisation, responder subtyping and in vivo validation, with the aim of building the efficacy and safety package required for further preclinical development.

Wiskott-Aldrich Syndrome Protein (WASp) is involved in actin regulation in haematopoietic cells. BIMINI is investigating modulation of this pathway as a differentiated therapeutic mechanism in leukaemia and lymphoma.

Dr. Digvijay Gahtory, CEO of BIMINI Biotech, said the investment would help advance the portfolio towards later preclinical development. LEH and Prof. Bertoni highlighted the potential value of novel mechanisms for patients whose cancers become resistant to existing therapies.

About BIMINI Biotech

BIMINI Biotech is a Leiden-based preclinical biotechnology company developing first-in-class small-molecule therapeutics targeting WASp.